FibroGen (FGEN) Given Daily News Sentiment Score of 0.13
News articles about FibroGen (NASDAQ:FGEN) have been trending somewhat positive recently, according to Accern Sentiment. The research group rates the sentiment of press coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. FibroGen earned a media sentiment score of 0.13 on Accern’s scale. Accern also assigned media stories about the biopharmaceutical company an impact score of 46.3403421130949 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Here are some of the news articles that may have effected Accern Sentiment’s rankings:
- K Peony Yu Sells 2,851 Shares of FibroGen, Inc (FGEN) Stock (americanbankingnews.com)
- Thomas B. Neff Sells 38,636 Shares of FibroGen, Inc (FGEN) Stock (americanbankingnews.com)
- FibroGen, Inc (FGEN) Director Sells $1,298,000.00 in Stock (americanbankingnews.com)
- FY2019 Earnings Estimate for FibroGen, Inc Issued By William Blair (FGEN) (americanbankingnews.com)
- FibroGen, Inc (NASDAQ:FGEN) Sees Heavy Trading Volume with 1363K Shares Changing Hands – First News 24 (firstnewspaper24.com)
A number of research firms have commented on FGEN. Jefferies Group LLC began coverage on shares of FibroGen in a research report on Monday, July 10th. They issued a “buy” rating and a $50.00 price target on the stock. Leerink Swann restated an “outperform” rating and issued a $82.00 price target (up from $52.00) on shares of FibroGen in a research report on Tuesday, August 8th. William Blair restated an “outperform” rating on shares of FibroGen in a research report on Wednesday, August 9th. Citigroup Inc. boosted their price target on shares of FibroGen from $48.00 to $65.00 and gave the company a “top pick” rating in a research report on Tuesday, August 8th. Finally, BidaskClub upgraded shares of FibroGen from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 24th. One research analyst has rated the stock with a sell rating, one has given a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $60.17.
FibroGen (NASDAQ:FGEN) opened at 52.40 on Friday. The firm’s market capitalization is $3.73 billion. FibroGen has a 12 month low of $15.60 and a 12 month high of $52.70. The stock’s 50 day moving average is $43.31 and its 200-day moving average is $32.07.
FibroGen (NASDAQ:FGEN) last posted its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.48) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.01). FibroGen had a negative net margin of 105.59% and a negative return on equity of 64.42%. The company had revenue of $29.00 million during the quarter, compared to analyst estimates of $34.80 million. Equities analysts anticipate that FibroGen will post ($1.80) earnings per share for the current fiscal year.
In related news, VP Pat Cotroneo sold 95,000 shares of FibroGen stock in a transaction that occurred on Tuesday, August 8th. The shares were sold at an average price of $50.61, for a total transaction of $4,807,950.00. Following the sale, the vice president now directly owns 173,366 shares in the company, valued at approximately $8,774,053.26. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Thomas B. Neff sold 38,636 shares of FibroGen stock in a transaction that occurred on Thursday, June 22nd. The stock was sold at an average price of $31.52, for a total transaction of $1,217,806.72. Following the sale, the chief executive officer now owns 3,330,780 shares in the company, valued at $104,986,185.60. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 509,328 shares of company stock worth $21,719,918. 14.90% of the stock is currently owned by corporate insiders.
FibroGen Company Profile
FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.
Receive News & Stock Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related stocks with our FREE daily email newsletter.